
ReproCELL Incorporated Investor Relations Material
Latest events

Q4 2025
14 May, 2025

Q3 2025
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ReproCELL Incorporated
Access all reports
ReproCELL Incorporated is a biotechnology company focused on advancing stem cell research and drug discovery. The company specializes in providing services and products for stem cell research, including iPSC-derived cell lines, media, and other culture reagents. It also offers predictive drug discovery services utilizing human tissues. ReproCELL's offerings support both preclinical and clinical research, with services tailored to meet regulatory standards across various global markets. Its portfolio includes advanced solutions for gene editing, stem cell therapy, and 3D cell culture systems, which cater to a wide range of scientific and medical applications. The company is headquartered in Yokohama, Kanagawa, Japan, and its shares are listed on the Tokyo Stock Exchange.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
4978
Country
🇯🇵 Japan